Fundraising Fox
/Companies
Sign in

Cerevance

Boston, US · Founded 2016 · 31 employees on LinkedIn · 16 known investors

Find your way into Cerevance

Each arrow is one introduction. Sign up to fill in the first one.

643 people can intro you to Ottavio

Ask John Glasspool to introduce you to Ottavio V. Vitolo

You →John · together at Relmada Therapeutics, Inc →Ottavio

282 people can intro you to Craig

Ask Jamie Chen to introduce you to Craig Thompson

You →Jamie · together at Anthera Pharmaceuticals →Craig

42 people can intro you to Sagar

Ask Sam Okafor to introduce you to Sagar Vaidya

You →Sam · together at Sangamo Therapeutics →Sagar

Sign up to find every way you can get introduced to Cerevance

  • Your email: who you already know at Cerevance, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Cerevance team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples. The company has multiple candidates in clinical development targeting Parkinson's disease, psychiatric conditions, ALS, and Alzheimer's disease.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

CTCraig Thompson
Craig ThompsonChief Executive OfficerCraig Thompson held leadership roles at Merck and Pfizer for nearly two decades before serving as president and CEO of multiple biotech companies including Neurana Pharmaceuticals, Anthera Pharmaceuticals, and Trius Therapeutics (where he co-led the acquisition by Cubist). He is currently CEO of Cerevance, which develops precision therapeutics for central nervous system disorders using a proprietary platform and human brain tissue library.
SVSagar Vaidya
Sagar VaidyaChief Medical OfficerHe is a physician-scientist and biotech executive with experience advancing drug development programs from pre-IND through late-stage clinical development across multiple therapeutic modalities including small molecules, biologics, and cell and gene therapies.
CA
Carrie Ann CookChief Business Officer
MCMark Carlton
Mark CarltonChief Scientific Officer
OVOttavio V. Vitolo
Ottavio V. VitoloChief Medical OfficerOttavio V. Vitolo is a neuropsychiatrist with over two decades of experience in clinical practice, translational neuroscience, and drug development; he founded New England Brain Health, serves as a physician at Massachusetts General Hospital and lecturer at Harvard Medical School, and brings expertise in neuroscience, rare disease therapeutics, clinical development strategy, and precision medicine approaches.

Investors · 16

Foresite Capital✓ confirmed by CerevanceWest Hollywood

How we know: Foresite Capital's portfolio page · the company's own site · Not right? Tell us

GV (Google Ventures)✓ confirmed by CerevanceMountain View · $250K – $50M

How we know: GV (Google Ventures)'s portfolio page · the company's own site · a partner's Signal profile · funding news · allsci.com · Not right? Tell us

SV Life Sciences✓ confirmed by CerevanceBoston

How we know: the company's own site · funding news · Not right? Tell us

Dementia Discoverylisted by Dementia DiscoveryLondon

How we know: Dementia Discovery's portfolio page · Not right? Tell us

Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco

How we know: Dolby Family Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Lightstone Ventureslisted by Lightstone VenturesPortola Valley

How we know: Lightstone Ventures's portfolio page · funding news · allsci.com · the VCSheet dataset · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · Not right? Tell us

Agent CapitalreportedWaltham

How we know: the VCSheet dataset · Not right? Tell us

MorgenthalerreportedPortola Valley

How we know: a partner's Signal profile · Not right? Tell us

Also in the syndicate · 6

Double Point VenturesGates FrontierMQB PartnersSV Health Investors' Dementia Discovery FundUPMCUPMC Enterprises

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Cerevance Raises $47M in Series B-1 Extensionfinsmes.com · Apr 2024Cerevance Expands Series B Financing with Additional $51Mfinsmes.com · Feb 2023

Frequently asked questions

What does Cerevance do?
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples. The company has multiple candidates in clinical development targeting Parkinson's disease, psychiatric conditions, ALS, and Alzheimer's disease.
Who are Cerevance's investors?
Cerevance's investors include Dementia Discovery Fund, Foresite Capital, GV (Google Ventures), SV Life Sciences, Dementia Discovery, Dolby Family Ventures, Lightstone Ventures, SV Health Investors and 2 more.
Where is Cerevance headquartered?
Cerevance is headquartered in Boston, US.